hydroxyurea has been researched along with Thromboembolism in 21 studies
Thromboembolism: Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 114 patients with essential thrombocythemia (77 women and 37 men; median age, 68 years; range, 40 to 85) and a median platelet count of 788,000 per cubic millimeter (range, 533,000 to 1,240,000 per cubic millimeter) were randomly assigned to receive hydroxyurea (56 patients) or no myelosuppressive therapy (58 patients)." | 9.08 | Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. ( Barbui, T; Cortelazzo, S; Finazzi, G; Galli, M; Rodeghiero, F; Ruggeri, M; Vestri, O, 1995) |
| " We present a unique case of ET causing extensive arterial thromboembolism, despite being on adequate antithrombotic agents including warfarin and aspirin." | 7.85 | Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure. ( Ahmed, AK; Skeik, N; Youssef, A, 2017) |
| "A total of 114 patients with essential thrombocythemia (77 women and 37 men; median age, 68 years; range, 40 to 85) and a median platelet count of 788,000 per cubic millimeter (range, 533,000 to 1,240,000 per cubic millimeter) were randomly assigned to receive hydroxyurea (56 patients) or no myelosuppressive therapy (58 patients)." | 5.08 | Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. ( Barbui, T; Cortelazzo, S; Finazzi, G; Galli, M; Rodeghiero, F; Ruggeri, M; Vestri, O, 1995) |
| " We present a unique case of ET causing extensive arterial thromboembolism, despite being on adequate antithrombotic agents including warfarin and aspirin." | 3.85 | Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure. ( Ahmed, AK; Skeik, N; Youssef, A, 2017) |
| " Accordingly, we conclude that clinical trials in SCD designed to increase the bioavailability of NO or association studies in which SCD clinical manifestations are related to plasma hemoglobin via its surrogates should be viewed with caution." | 2.46 | Pulmonary hypertension and nitric oxide depletion in sickle cell disease. ( Bunn, HF; Dover, GJ; Hebbel, RP; Nathan, DG; Platt, OS; Rosse, WF; Ware, RE, 2010) |
| "A case of acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) is reported." | 1.32 | [All-trans retinoic acid for thromboembolic events in patients with M3 leukemia: a case report]. ( Feng, R; Jiang, ZJ; Liu, XL; Meng, FY; Yin, F; Zheng, WY; Zhou, SY, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 8 (38.10) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, HS | 1 |
| Hong, J | 1 |
| Hwang, SM | 1 |
| Lee, JH | 1 |
| Ma, Y | 1 |
| Kim, SA | 1 |
| Lee, JY | 1 |
| Lee, JO | 1 |
| Bang, SM | 1 |
| Parasuraman, SV | 1 |
| Shi, N | 1 |
| Paranagama, DC | 1 |
| Bonafede, M | 1 |
| Griesshammer, M | 1 |
| Kiladjian, JJ | 1 |
| Besses, C | 1 |
| Aumiller, J | 1 |
| Ahmed, AK | 1 |
| Youssef, A | 1 |
| Skeik, N | 1 |
| Ali, FR | 1 |
| Roberts, LN | 1 |
| Mistry, H | 1 |
| Patel, RK | 1 |
| Edmondson, RA | 1 |
| Arya, R | 1 |
| Bunn, HF | 1 |
| Nathan, DG | 1 |
| Dover, GJ | 1 |
| Hebbel, RP | 1 |
| Platt, OS | 1 |
| Rosse, WF | 1 |
| Ware, RE | 1 |
| Novelli, EM | 1 |
| Kato, GJ | 1 |
| Ragni, MV | 1 |
| Zhang, Y | 1 |
| Hildesheim, ME | 1 |
| Nouraie, M | 1 |
| Barge, S | 1 |
| Meyer, MP | 1 |
| Hassett, AC | 1 |
| Gordeuk, VR | 1 |
| Gladwin, MT | 1 |
| Isenberg, JS | 1 |
| Gemünden, C | 1 |
| Gerber, B | 1 |
| Yin, F | 1 |
| Zheng, WY | 1 |
| Meng, FY | 1 |
| Jiang, ZJ | 1 |
| Liu, XL | 1 |
| Feng, R | 1 |
| Zhou, SY | 1 |
| Gabriel, L | 1 |
| de Meester, A | 1 |
| Cazzola, M | 2 |
| Petrides, PE | 1 |
| Passamonti, F | 1 |
| Spry, CJ | 1 |
| Cortelazzo, S | 1 |
| Finazzi, G | 1 |
| Ruggeri, M | 1 |
| Vestri, O | 1 |
| Galli, M | 1 |
| Rodeghiero, F | 1 |
| Barbui, T | 1 |
| Rose, C | 1 |
| Bauters, F | 1 |
| Galacteros, F | 1 |
| Lengfelder, E | 1 |
| Hehlmann, R | 1 |
| Rezaei Kalantari, H | 1 |
| Schafer, AI | 1 |
| Mercadanti, M | 1 |
| Cavalieri, F | 1 |
| Ferraccioli, GF | 1 |
| Ambanelli, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Substudy of the CADRE Study: Determination of Clinical Markers in Patients With Extreme Sickle Cell Disease Phenotype[NCT03352986] | 300 participants (Anticipated) | Observational | 2017-05-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for hydroxyurea and Thromboembolism
| Article | Year |
|---|---|
Pulmonary hypertension and nitric oxide depletion in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Animals; Child; Clinical Trials as Topic; Disease Models, Animal; Echoca | 2010 |
Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.
Topics: Animals; Carcinogens; Clinical Trials as Topic; Drug Therapy, Combination; Heart Diseases; Humans; H | 2004 |
The hypereosinophilic syndrome: clinical features, laboratory findings and treatment.
Topics: Anticoagulants; Bone Marrow; Central Nervous System Diseases; Endomyocardial Fibrosis; Eosinophilia; | 1982 |
[Polycythemia vera: current status of therapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bloodletting; Clinical Trials | 2000 |
[How I treat ... sickle cell anemia: current therapies].
Topics: Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antisickling Agents; A | 2001 |
Essential thrombocythemia.
Topics: Abortion, Habitual; Age Factors; Blood Platelets; Combined Modality Therapy; Diagnosis, Differential | 1991 |
2 trials available for hydroxyurea and Thromboembolism
| Article | Year |
|---|---|
Thromboembolic events in polycythemia vera.
Topics: Age Factors; Anticoagulants; Aspirin; Humans; Hydroxyurea; Interferons; Nitriles; Phlebotomy; Polycy | 2019 |
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Female; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; | 1995 |
13 other studies available for hydroxyurea and Thromboembolism
| Article | Year |
|---|---|
Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
Topics: Adolescent; Adult; Antineoplastic Agents; Aspirin; Child; Female; Fibrinolytic Agents; Follow-Up Stu | 2021 |
Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cross-Sectional Studies; Drug Resistance, Neoplasm; | 2018 |
[Polycythemia vera: the disadvantages of overproduction].
Topics: Aged; Aspirin; Bloodletting; Diagnosis, Differential; Female; Hematocrit; Humans; Hydroxyurea; Inter | 2015 |
Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure.
Topics: Anticoagulants; Arterial Occlusive Diseases; Blood Coagulation; Blood Coagulation Tests; Computed To | 2017 |
Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation.
Topics: Anticoagulants; Arterial Occlusive Diseases; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; | 2009 |
Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates.
Topics: Acute Chest Syndrome; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Cohort Studies; F | 2012 |
[Polycythemia vera].
Topics: Aged; Algorithms; Alleles; Bone Marrow Examination; Diagnosis, Differential; Erythropoietin; Female; | 2012 |
[All-trans retinoic acid for thromboembolic events in patients with M3 leukemia: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Humans; Hydroxyurea; Leukemia, | 2003 |
Myocardial infarction and primary thrombocytosis in a young man.
Topics: Adult; Antineoplastic Agents; Coronary Angiography; Electrocardiography; Fibrinolytic Agents; Humans | 2003 |
Towards a rational treatment of essential thrombocythemia, despite limited evidence and old prejudices.
Topics: Adult; Cohort Studies; Disease Progression; Evidence-Based Medicine; Expert Testimony; Female; Hemor | 2004 |
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.
Topics: Adult; Humans; Hydroxyurea; Middle Aged; Pipobroman; Platelet Aggregation Inhibitors; Prognosis; Ris | 2004 |
Hydroxyurea therapy in highly unstable hemoglobin carriers.
Topics: Adult; Anemia, Hemolytic; Combined Modality Therapy; Female; Fetal Hemoglobin; Gene Expression Regul | 1996 |
[Idiopathic hypereosinophilic syndrome. Current clinico-therapeutic state].
Topics: Adrenal Cortex Hormones; Adult; Antibody Formation; Anticoagulants; Blood Proteins; Cardiomyopathies | 1985 |